Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?
(2015) In Current Hematologic Malignancy Reports 10(3). p.309-317- Abstract
This review focuses on the most recent literature concerning flow cytometry (FCM) application for diagnosis of myelodysplastic syndrome (MDS). Aberrant FCM results have been defined as abnormalities in at least three tested features comprising at least two bone marrow (BM) cell compartments. FCM results should be interpreted together with the BM smear cytology, the morphological assessment of BM biopsy, and cytogenetic results. Including FCM in the pre-treatment assessment may provide not only diagnostic but also prognostic information. Further studies are needed to evaluate the role of FCM in individual risk assessment for MDS patients and in therapy choice and/or follow-up.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5f1c7ddc-d553-4cd9-a3da-302490a5e48d
- author
- Porwit, Anna LU
- publishing date
- 2015-09-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Diagnosis, Dysplasia, Flow cytometry, Myelodysplastic syndromes, Prognosis, Response to treatment
- in
- Current Hematologic Malignancy Reports
- volume
- 10
- issue
- 3
- pages
- 9 pages
- publisher
- Springer
- external identifiers
-
- pmid:26122389
- scopus:84941738249
- ISSN
- 1558-8211
- DOI
- 10.1007/s11899-015-0272-3
- language
- English
- LU publication?
- no
- id
- 5f1c7ddc-d553-4cd9-a3da-302490a5e48d
- date added to LUP
- 2019-05-22 09:43:37
- date last changed
- 2024-04-30 09:17:11
@article{5f1c7ddc-d553-4cd9-a3da-302490a5e48d, abstract = {{<p>This review focuses on the most recent literature concerning flow cytometry (FCM) application for diagnosis of myelodysplastic syndrome (MDS). Aberrant FCM results have been defined as abnormalities in at least three tested features comprising at least two bone marrow (BM) cell compartments. FCM results should be interpreted together with the BM smear cytology, the morphological assessment of BM biopsy, and cytogenetic results. Including FCM in the pre-treatment assessment may provide not only diagnostic but also prognostic information. Further studies are needed to evaluate the role of FCM in individual risk assessment for MDS patients and in therapy choice and/or follow-up.</p>}}, author = {{Porwit, Anna}}, issn = {{1558-8211}}, keywords = {{Diagnosis; Dysplasia; Flow cytometry; Myelodysplastic syndromes; Prognosis; Response to treatment}}, language = {{eng}}, month = {{09}}, number = {{3}}, pages = {{309--317}}, publisher = {{Springer}}, series = {{Current Hematologic Malignancy Reports}}, title = {{Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?}}, url = {{http://dx.doi.org/10.1007/s11899-015-0272-3}}, doi = {{10.1007/s11899-015-0272-3}}, volume = {{10}}, year = {{2015}}, }